바로가기  >

Abstract
Albumin is one of the most attractive nanoplatforms for targeted imaging and drug delivery due to its biocompatibility and long circulation half-life. However, previously reported albumin-based nanoplatforms have shown inconsistent blood circulation half-life according to the modified methods, and the affecting factors were not well evaluated, which could hamper the clinical translation of albumin-based nanoplatforms. Herein, we developed a finely tuned click-chemistry based albumin nanoplatform (CAN) with a longer circulation half-life and an efficient tumor targeting ability.

Author information

Ji Yong Park1,5*, Myung Geun Song1,8*, Woo Hyoung Kim10*, Kyu Wan Kim1, Nadeem Ahmed Lodhi1,7, Jin Yeong Choi2, Young Ju Kim1,3,4, Jung Young Kim6, Hyewon Chung9, Chiwoo Oh2, Yun-Sang Lee1,3  , Keon Wook Kang1,3,4  , Hyung-Jun Im2  , Seung Hyeok Seok9, Dong Soo Lee1,2, Edmund E. Kim1, Jae Min Jeong1,3,4

1. Department of Nuclear Medicine, Seoul National University Hospital, College of Medicine, Seoul, South Korea.
2. Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.
3. Radiation Medicine Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
4. Cancer Research Institute, Seoul National University, Seoul, South Korea.
5. Department of Biomedical Sciences, Seoul National University, Seoul, South Korea.
6. Department of RI Technology-Convergence, Korean Institute of Radiological & Medical Sciences (KIRAMS), Seoul, South Korea.
7. Isotope Production Division, Pakistan Institute of Nuclear Science & Technology (PINSTECH), P. O, Nilore, Islamabad.
8. Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.
9. Department of Microbiology and Immunology, Institute of Endemic Disease, College of Medicine, Seoul National University, Seoul, South Korea.
10. Division of Pharmaceuticals and Clinical Development, DawonMedax Co., Ltd., Seoul, South Korea.
* These authors contributed equally.